APEX2 and pancreatic neoplasm: APE2’s exonuclease activity, enhanced by PCNA, creates longer ssDNA gaps (∼18–26 nt), which allow robust RPA coating and full ATR checkpoint assembly as shown in pancreatic cancer cells [101] (Fig. 4A).